"Brain-computer interfaces are entering a moment similar to earlier chapters in neuromodulation, when decades of scientific and technical progress begin to become routine clinical care." - William J. Marks, Jr., MD, MS
That perspective reflects the clinical discipline, translational experience, and long-term view required to move BCI from breakthrough technology toward trusted care.
That is why we are honored to welcome Bill Marks as Paradromics' new Chief Clinical Officer. Dr. Marks spent nearly two decades at UCSF, helped shape Medtronic's global deep brain stimulation business, and built clinical science organizations at Verily.
Weeks after the first human implantation of the Connexus® BCI, he will help guide the clinical strategy that carries Paradromics from these early milestones toward trusted, global care.
Read the full release to learn more: https://t.co/ocdFLbq4wA
What I think is under-discussed with @jito_sol launching @jtx_trade is the connection between BAM plugins and the front end.
The edge is not just infra expertise. It is that JTX can become the surface where BAM primitives turn into better trading workflows: protected flow, better limit/cancel behavior, and more advanced order types.
There is a massive gap in the market for this as onchain trading matures.
CC @blknoiz06
July release coming up soon: https://t.co/ECCdhWtPAk